Bioretec has been rebuilding its commercial foundation during 2025 and is seeking to restore damaged investor confidence. To finance its growth strategy, the company announced it is considering a 15 MEUR share issue. Bioretec's CEO Sarah Hubar-Fisher in an interview with analyst Antti Siltanen.

Topics:

00:00 Introduction

00:15 Bioretec’s year 2025

00:45 Main reasons for stalled growth

02:21 The commercial progress of RemeOs

03:26 Situation in China

04:30 Chances in go-to-market strategy

05:22 Most important things to achieve in the US this year

06:40 Outlook for broadening the portfolio and expanding indications

07:47 Situation in Europe

08:51 Finnish hospitals

09:28 Partnership possibilities

10:38 KPI reporting

12:59 Plans regarding funding